InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Fiscal 2026 Results, Highlights Phase 3 Progress
June 29, 2026
This NewsBreak has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) reported fiscal 2026 financial results and provided an update on its clinical pipeline, highlighting continued progress of its lead candidate HLP003 for major depressive disorder. The company said its Phase 3 APPROACH trial […]
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Closes $50 Million Public Offering
June 25, 2026
This article has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced the closing of its previously announced underwritten public offering of 10,309,280 common shares at a price of US$4.85 per share, generating gross proceeds of approximately US$50 million. Cantor and Barclays served as joint bookrunning managers for the offering, with Bloom Burton […]
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Prices $50 Million Public Offering
June 24, 2026
This article has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced the pricing of an underwritten public offering of 10.3 million common shares at $4.85 per share, generating gross proceeds of approximately $50 million. Cantor and Barclays are serving as joint bookrunning managers for the offering, which is expected to close on […]
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Surpasses 86% Enrollment in Phase 3 APPROACH Trial
June 24, 2026
This article has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced that enrollment in its Phase 3 APPROACH clinical trial evaluating HLP003 for the adjunctive treatment of major depressive disorder has surpassed 86% and remains on track. The study is one of the company’s Phase 3 trials supporting development of HLP003, its lead […]
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Chief Medical Officer to Participate in H.C. Wainwright Neuro Perspectives Conference
June 11, 2026
This NewsBreak has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, announced that Chief Medical Officer Amir Inamdar will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference, taking place […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) to Host First R&D Webcast Highlighting Phase 2a Oncology Program
June 8, 2026
TransCode Therapeutics (NASDAQ: RNAZ) announced it will host its first live virtual R&D webcast on June 18, 2026, to provide strategic, scientific and clinical updates across its development pipeline. The presentation will be anchored by the company’s recently initiated Phase 2a clinical trial of TTX-MC138 in circulating tumor DNA-positive colorectal cancer and will also include […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Reports Positive Phase 1a Results for TTX-MC138 and Advances Program Toward Phase 2a
June 3, 2026
TransCode Therapeutics (NASDAQ: RNAZ) announced additional results from its Phase 1a dose-escalation trial evaluating TTX-MC138, an investigational microRNA-10b inhibitor for advanced cancer. The study met its primary safety endpoint, with no dose-limiting toxicities observed across 16 patients who received a total of 86 doses. The company reported durable disease stabilization in multiple patients, including three participants who remain on treatment after 14, 16 […]
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) to Participate in Jefferies Global Healthcare Conference
June 1, 2026
This article has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, announced that Interim Chief Executive Officer Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The discussion is scheduled for June 4, 2026, at 2:35 p.m. EDT and […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Initiates Phase 2a Trial of TTX-MC138 in Colorectal Cancer Patients with Minimal Residual Disease
May 27, 2026
TransCode Therapeutics (NASDAQ: RNAZ) announced the initiation of a Phase 2a clinical trial evaluating its lead therapeutic candidate, TTX-MC138, in up to 45 colorectal cancer patients who remain circulating tumor DNA-positive following curative-intent therapy despite no radiographic evidence of disease, indicating minimal residual disease. Conducted in collaboration with Quantum Leap Healthcare Collaborative through its PRE-I-SPY clinical trial platform, the study will […]
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Issues Correction To TARA Mind Partnership Announcement
May 1, 2026
This NewsBreak has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, issued a correction to its April 28, 2026 release regarding its partnership with TARA Mind to support Phase 3 recruitment for its HLP003 program in […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Scientific Advisory Board Chair, Signs Research Agreement With Michigan State University
April 27, 2026
TransCode Therapeutics (NASDAQ: RNAZ) announced the appointment of Anna Moore, PhD, as Chair of its Scientific Advisory Board and the execution of a sponsored research agreement with Michigan State University aimed at advancing its RNA-based therapeutic pipeline. The agreement is expected to support development of the Company’s lead candidate, TTX-MC138, including evaluation in combination with […]
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Adds Robert Langer, Stephen Brannan To Scientific Advisory Board
April 23, 2026
This NewsBreak has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced the appointments of Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, strengthening its expertise in biotechnology, drug delivery and central nervous system clinical development as the company advances […]
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Supports Executive Order Advancing Psychedelic Therapies
April 20, 2026
This article has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) welcomed a White House Executive Order aimed at accelerating research, regulatory pathways and patient access to psychedelic treatments, citing its potential to prioritize FDA review, expand access and strengthen interagency coordination. The company highlighted its Phase 3 HLP003 program, which has received Breakthrough Therapy designation […]
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO Steps Down, Eric So Named Interim Chief Executive Office
April 20, 2026
This article has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced that Michael Cola has stepped down as Chief Executive Officer effective immediately at the request of the Board, with Co-founder and Executive Chairman Eric So appointed as Interim CEO while a search for a permanent successor is underway. The company said the leadership transition is […]
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Dr. Ken Kramer SVP Medical Affairs
April 16, 2026
This NewsBreak has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (“NSAs”), announced the appointment of Dr. Ken Kramer, PhD, as senior vice president of medical affairs, effective immediately. Kramer brings more than 20 years of […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Secures Up to $20 Million Financing Agreement
April 7, 2026
TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company focused on immuno-oncology and RNA-based therapies, announced that it has entered into a financing agreement with an institutional healthcare investor for up to $20 million. The arrangement includes up to $6 million in pre-paid advances and a three-year Standby Equity Purchase Agreement allowing the company to sell up to $14 […]
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Jill Conwell as Chief People Officer
March 12, 2026
This NewsBreak has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (“NSAs”) to address mental health conditions, announced the appointment of Jill Conwell as chief people officer, effective immediately. Conwell brings more than 20 years of […]
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Positive Phase 2 Results for HLP004 in Generalized Anxiety Disorder
March 5, 2026
This NewsBreak has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) a clinical-stage pharmaceutical company developing novel serotonergic agonists (“NSAs”) for serious mental health conditions, today reported topline results from a Phase 2 signal detection study evaluating HLP004 as a potential adjunctive treatment for adults with moderate-to-severe generalized anxiety disorder (“GAD”) who remained […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Secures Exclusive Global License to Three Unleash Immuno-Oncolytics Drug Candidates
March 3, 2026
TransCode Therapeutics (NASDAQ: RNAZ) announced it has entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc., obtaining rights to develop three drug candidates — UIO-524, UIO-525 and UIO-526 — including all in-licensed and owned rights held by Unleash. Under the agreement, Unleash will receive a one-time payment of 1,136,364 […]
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Dr. Freda Lewis-Hall to Board and Scientific Advisory Committee Chair
February 24, 2026
This NewsBreak has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced the appointment of Dr. Freda Lewis-Hall, DFAPA, MFPM, to its board of directors, where she will also serve as chair of the company’s Scientific Advisory Committee, subject to approval by Cboe Canada. […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Announces Publication On Tumor-Selective RIG-I Immunotherapy Approach
February 23, 2026
TransCode Therapeutics (NASDAQ: RNAZ) announced the publication of a manuscript in Molecular Imaging and Biology detailing a novel tumor-selective immunotherapy strategy that activates RIG-I signaling within cancer cells while enabling non-invasive imaging of drug delivery. The study, conducted in collaboration with Michigan State University researcher Dr. Anna Moore, describes a template-directed RIG-I agonist approach leveraging […]
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Positive Phase 2a SPL026 Data Published in Nature Medicine
February 17, 2026
This NewsBreak has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced publication in Nature Medicine of Phase 2a trial results showing that a single 21.5 mg dose of SPL026 achieved statistically significant and clinically meaningful reductions in depressive symptoms versus placebo in patients […]
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Q3 2025 Results, Advances Phase 3 and Phase 2 Programs
February 13, 2026
This article has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, reported unaudited financial results for the third quarter ended Dec. 31, 2025, highlighting continued progress across its HLP003 Phase 3 program for major depressive disorder and HLP004 Phase 2 program for generalized anxiety disorder, […]
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Michael Cola as Chief Executive Officer
February 10, 2026
This article has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists to address serious mental health disorders, announced the appointment of Michael Cola as Chief Executive Officer, effective immediately, as the Company advances its pipeline toward key clinical and corporate milestones, including expected Phase 2 […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Submits IND Amendment for Planned Phase 2a Trial of TTX-MC138 in Colorectal Cancer
February 5, 2026
TransCode Therapeutics (NASDAQ: RNAZ) announced the submission of an Investigational New Drug (“IND”) application amendment to the U.S. Food and Drug Administration for a planned Phase 2a clinical trial of its lead candidate, TTX-MC138, to be conducted by Quantum Leap Healthcare Collaborative within the PRE-I-SPY program. The dose-expansion study is expected to enroll up to […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Publishes Preclinical Data Supporting TTX-MC138 for Glioblastoma
January 6, 2026
TransCode Therapeutics (NASDAQ: RNAZ) announced the publication of peer-reviewed preclinical research supporting the use of its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme, one of the most aggressive forms of brain cancer. The study, conducted in collaboration with Michigan State University and published in the Journal of Functional Biomaterials, demonstrated that systemic delivery of TTX-MC138 successfully reached brain tumors in […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Jack E. Stover to Board of Directors
December 22, 2025
TransCode Therapeutics (NASDAQ: RNAZ) announced the appointment of Jack E. Stover to its Board of Directors, where he will serve on the Audit Committee and the Nominating Committee, as Dr. Magda Marquet steps down from the Audit Committee. Mr. Stover brings more than 30 years of executive leadership experience across public and private life sciences companies, with a background spanning […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Launch Collaboration to Evaluate TTX-MC138 in PRE-I-SPY Trial
December 11, 2025
TransCode Therapeutics (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative announced a collaboration to evaluate TransCode’s lead therapeutic candidate TTX-MC138 in the PRE-I-SPY Phase 2a clinical trial platform, which plans to enroll up to 45 colorectal cancer patients who are ctDNA positive following standard curative-intent therapy. Beginning in the first half of 2026 and led by […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Dr. Michel Janicot as Senior Development Officer
November 17, 2025
TransCode Therapeutics (NASDAQ: RNAZ) appointed Dr. Michel Janicot as consultant Senior Development Officer, adding more than 35 years of global oncology drug-development experience to support the advancement of TTX-MC138 and Seviprotimut-L. Dr. Janicot, founder of JMi ONConsulting and former senior leader at Rhône-Poulenc Rorer and Janssen, brings deep expertise in RNA biology, preclinical strategy, translational […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Completes Phase 1a Trial of TTX-MC138, Advancing to Phase 2 Evaluation
October 14, 2025
TransCode Therapeutics (NASDAQ: RNAZ) announced completion of its Phase 1a clinical trial of TTX-MC138, an investigational inhibitor of microRNA-10b, achieving its primary safety endpoint and establishing a recommended Phase 2 dose. Sixteen patients were treated with no significant safety events or dose-limiting toxicities observed, and 44% achieved stable disease lasting four months or longer. The […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Acquires Polynoma, Secures $25 Million Investment from CK Life Sciences to Advance Phase 2 Trial of TTX-MC138
October 8, 2025
TransCode Therapeutics (NASDAQ: RNAZ) announced it has entered into a definitive agreement to acquire Polynoma LLC, a privately held immuno-oncology company developing seviprotimut-L, a late-stage polyvalent shed antigen vaccine for the adjuvant treatment of stage IIB and IIC melanoma. Concurrent with the acquisition, TransCode secured a $25 million investment from CK Life Sciences Int’l (Holdings) […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints RNAi Pioneer Phillip Zamore to Scientific Advisory Board
May 28, 2025
TransCode Therapeutics (NASDAQ: RNAZ), has appointed Dr. Phillip D. Zamore, a leading figure in RNA interference (RNAi) research and co-founder of Alnylam Pharmaceuticals, to its Scientific Advisory Board. Dr. Zamore, currently Chair of the RNA Therapeutics Institute at UMass Chan Medical School, is renowned for his foundational work in RNA biology and gene silencing mechanisms. […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Advances RNA Cancer Therapy as 15 Patients Dosed in Phase 1a Trial
May 8, 2025
TransCode Therapeutics (NASDAQ: RNAZ) announced that the third patient in Cohort 4 of its Phase 1a trial for RNA-based cancer therapeutic TTX-MC138 has been dosed, with 15 patients now treated across four dose levels. The Safety Review Committee approved expanded enrollment and noted no significant toxicities or disease progression to date. Ten patients remain on […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Sets 1-for-28 Reverse Stock Split Effective May 15
May 6, 2025
TransCode Therapeutics (NASDAQ: RNAZ), the RNA oncology company focused on developing RNA therapeutics to treat cancer, will implement a 1-for-28 reverse stock split effective May 15, 2025, at 12:01 a.m. EDT. Shares will begin trading on a split-adjusted basis that same day under the existing ticker, “RNAZ.” The move, approved by shareholders and the board, […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138
May 1, 2025
TransCode Therapeutics (NASDAQ: RNAZ) reported continued progress in its Phase 1a trial of TTX-MC138, an RNA-based therapeutic targeting microRNA-10b in metastatic cancer. Thirteen patients have received at least one dose across four dosing levels, with no significant toxicities observed. Eight patients remain in the trial, with two showing stable disease after seven months. Early PK/PD […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Adjourns Special Meeting Due to Lack of Quorum
April 22, 2025
TransCode Therapeutics (NASDAQ: RNAZ) announced that its April 21 special meeting has been adjourned to May 2 at 9:30 a.m. Eastern after failing to meet the quorum requirement. Only 12.73% of eligible shares were represented, below the one-third threshold. The adjournment is intended to allow further proxy solicitation on two proposals: a reverse stock split […]
InvestorNewsBreaks – TransCode Therapeutics Inc. (NASDAQ: RNAZ) Secures $10M in Registered Direct Offering
March 27, 2025
TransCode (NASDAQ: RNAZ), the oncology company committed to utilizing RNA therapeutics to more effectively treat cancer, has announced the closing of its sale of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and […]
ROTH MKM to Host 9th Annual London Conference on June 20-22, 2023
June 13, 2023
NEWPORT BEACH, Calif., June 13, 2023 (GLOBE NEWSWIRE) — via IBN — ROTH MKM (“Roth”), www.roth.com, will host the 9th Annual Roth London Conference on June 20-22, 2023, at Four Seasons Hotel London at Park Lane in London, UK. This event will provide institutional investors the unique opportunity to meet with C-suite leaders and executive management teams from approximately 70 […]
Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90+ Companies
November 15, 2021
Virtual: November 16 – 17, 2021 Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand for hosting North America’s largest independent investor conferences. Over 90 presenting companies from a wide spectrum […]